IMMX Immix Biopharma Company Short-Term Debt

immixbio.com - graphic logo of issuer IMMX

Geopolitical risks are hindering international trials for Immix Biopharma, Inc. (IMMX), while a lack of sales leaves the business dependent on external financing. Financial liabilities with a maturity of up to one year on the GURU.Markets chart soften this contrast, where the current amount is 0.00. The company is currently focusing on accelerating CAR-T asset trials through partnerships with medical centers.

IMMX Immix Short-Term Debt (07/04/2022 - 10/31/2026)

Analytical breakdowns and data insights for company Immix Biopharma Inc. (IMMX)

- current quotes and average value forecast:
Price Chart Immix|IMMX - Average Forecast Price
- market capitalization data:
Market Value Immix Biopharma, Inc.|IMMX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Immix Biopharma|IMMX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio immixbio.com|IMMX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Immix Biopharma, Inc.|IMMX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Immix|IMMX - Aggregate Debt Obligations|Debts to Book Capitalization Immix Biopharma, Inc.|IMMX - Long-Term Debt Volume|Company Short-Term Debt Immix Biopharma|Quick Liquidity immixbio.com
- earnings and multiples data:
IMMX - Net Income
General company analysis:immixbio.com (IMMX)
Flagship merchandise of Immix Biopharma, Inc.

For Immix Biopharma, Inc. (IMMX), whose viability depends on clinical trial outcomes and a high burn rate, liquidity control is a critical survival factor. By analyzing the short-term debt chart, an investor assesses obligations maturing within one year to differentiate strategic scaling of the R&D pipeline from a dangerous approach toward a cash crunch in the absence of stable revenue.

Competitors of Immix Biopharma, Inc.

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)